Management of hypertension in solid-organ transplantation

Progress in Transplantation

Volumn 15, Issue 1, 2005, Pages 17-22

  Park, Jeong M ^a   Luan, Fu L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; LOOP DIURETIC AGENT; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; VERAPAMIL; ANTIHYPERTENSIVE AGENT;

ANAMNESIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC ALLOGRAFT NEPHROPATHY; COMORBIDITY; CREATININE CLEARANCE; DRUG EFFECT; DYSLIPIDEMIA; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION TEST; KIDNEY VASCULAR RESISTANCE; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION; TREATMENT PLANNING;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; ORGAN TRANSPLANTATION;

EID: 19844374974     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.1177/152692480501500103     Document Type: Review

References (64)

1. US Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md. 2002-2003. Available at: http://www.usrds.org/reference.htm. Accessed August 11, 2003.
2. Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transplant. 2001;7:811-815.
3. Vogt DP, Henderson JM, Carey WD, et al. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery. 2002;132:775-780.
4. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality. Lancet. 2002;360:1903-1903.
5. Neal B, MacMahon S, Chapman N, et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet. 2000;356:1955-1964.
6. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipients blood pressure. Kidney Int. 1998;53:217-222.
7. Jensik SC. Tacrolimus (FK 506) in kidney transplantation: three-year results of the US multicenter, randomized, comparative trial. Transplant Proc. 1998;30:1216-1218.
8. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation:evidence for improved allograft survival at five years. Transplantation. 2002;73:775-782.
9. Otto MG, Mayer AD, Clavien PA, Cavallari A, Gunawardena KA, Mueller EA. A long-term comparison of tacrolimus (FK 506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73:775-782.
10. Canzanello VJ, Textor SC, Taler SJ, et al. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transplant Surg. 1998;4:328-334.
11. Eisen HJ, Hobbs RE, Davis SF, et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine - results at 24 months after transplantation. Transplantation. 2001;71:70-78.
12. Eisen HJ, Hobbs RE, Davis SF, et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine - results at six months after transplantation. Transplantation. 1999;68:663-671.
13. Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 1987;31:1213-1224.
14. Hricik DE, Lautman J, Bartucci MR, et al. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated transplant recipients. Transplantation. 1992;53:1232-1236.
15. Moss NG, Powell SL, Falk RJ. Intravenous cycloserine acticates afferent and efferent renal nerves and causes sodium retension in innervated kidneys in rats. Proc Natl Acad Sci USA. 1985;82:8222-8226.
16. Marsen TA, Weber F, Egink G, Suckau G, Baldamus CA. Cyclosporine A induces prepro endothelin-1 gene transcription in human endothelial cells. Eur J Pharmacol. 1999;379:97-106.
17. Oriji GK, Keiser HR. Nitric oxide in cyclosporine A-induced hypertension: role of protein kinase C. Am J Hypertens. 1999;12:1091-1097.
18. Scherrer U, Vissin SF, Morgan BJ, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med. 1990;323:693-699.
19. Avdonin PV, Cottet-Marie F, Afanasjeva GV, et al. Cyclosporine A upregulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int. 1999;55:2407-2414.
20. Textor SC. De novo hypertension after liver transplantation. Hypertension. 1993;22:257-267.
21. Wong W, Fyn SP, Higgins RM, et al. Transplant renal artery stenosis in 77 patients - does it have an immunological cause? Transplantation. 1996;61:215-219.
22. Fervenza FC, Lafayette RA, Alfrey EJ, Petersen J. Renal artery stenosis in kidney transplants [review]. Am J Kidney Dis. 1998;31:142-148.
23. Ducloux D, Motte G, Kribs M, et al. Hypertension in renal transplantation: donor and recipient risk factors. Clin Nephrol. 2002;57:409-413.
24. Vanrenterghem Y, Waer M, Christiaes MR, Michielsen P. Bilateral nephrectomy of the native kidneys reduces the incidence of arterial hypertension and erythrocytosis in kidney graft recipients treated with cyclosporin. Transplant Int. 1992;5(suppl 1):S35-37.
25. Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol. 2000;20:126-147.
26. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
27. Mange KC, Feldman HI, Joffe MM, Fa K, Bloom RD. Blood pressure and the survival of renal allografts from living donors. J Am Soc Nephrol. 2004;15:187-193.
28. Olyaei AJ, deMattos AM, Bennett WM. A practical guide to the management of hypertension in renal transplant recipients. Drugs. 1999;58:1011-1027.
29. Baroletti SA, Gabardi S, Magee CC, et al. Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. Pharmacotherapy. 2003;23:788-801.
30. Schlueter WA, Batlle DC. Renal effects of antihypertensive drugs. Drugs. 1989;37:900-925.
31. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
32. Venkat-Raman G, Feehally J, Elliot HL, et al. Renal and haemodynamic effects of amlodipine and nifedipine in hypertensive renal transplant recipients. Nephrol Dial Transplant. 1998;13:2612-2616.
33. Wagner K, Albrecht S, Neumayer HH. Prevention of post-transplant acute tubular necrosis by the calcium antagonist diltiazem: a prospective randomized study. Am J Nephrol. 1987;7:287-291.
34. McMillen MA, Lewis T, Jaffe BM, et al. Verapamil inhibition of lymphocyte proliferation and function in vitro. J Surg Res. 1985;39:76-80.
35. Birx DL, Berger M, Fleisher TA. The interference of T cell activation by calcium channel blocking agents. J Immunol. 1984;133:2904-2909.
36. Palmer BF, Dawidson I, Sagalowsky A, et al. Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation. 1991;52:640-645.
37. Rump LC, Oberhauser V, Schwertfeger E, et al. Dihydropyridine calcium antagonists and renal function in hypertensive kidney transplant recipients. J Hypertens. 2000;18:1115-1119.
38. van Riemsdijk IC, Mulder PG, de Fijter JW, et al. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. Transplantation. 2000;70:122-126.
39. James JA, Marley JJ, Jamal S, et al. The calcium channel blocker used with cyclosporin has an effect in gingival overgrowth. J Clin Periodontal. 2000;27:109-115.
40. Khoori AH, Einollahi B, Ansari G, et al. The effect of cyclosporine with and without nifedipine on gingival overgrowth in renal transplant patients. J Can Dent Assoc. 2003;69:236-241.
41. Asberg A, Christensen H, Hartmann A, Carlson E, Molden E, Berg KJ. Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients. Eur J Clin Pharmacol. 1999;55:383-387.
42. Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother. 1999;33:680-682.
43. Guan D, Wang R, Lu J, Wang M, Xu C. Effects of nicardipine on blood cyclosporine levels in renal transplant patients. Transplant Proc. 1996;28:1311-1312.
44. Crocker JF, Renton KW, LeVatte TL, McLellan DH. The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients. Pediatr Nephrol. 1994;8:408-411.
45. Pesavento TE, Jones PA, Julian BA, Curtis JJ. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol. 1996;7:831-835.
46. Toupance O, Lavaud S, Canivet E, Bernaud C, Hotton JM, Chanard J. Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. Hypertension. 1994;24:297-300.
47. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
48. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345: 861-869.
49. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
50. Wright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002;162:1636-1643.
51. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
52. Curtis JJ, Laskow DA, Jones PA, Julian BA, Gaston RS, Luke RG. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol. 1993;3:1570-1574.
53. Hausberg M, Kosch M, Hohage H, et al. Antihypertensive treatment in renal transplant patients-is there a role for ACE inhibitors? Ann Transplant. 2001;6:31-37.
54. Remuzzi G, Peric N. Routine renin-angiotensin system blockade in renal transplantation? Curr Opin Nephrol Hypertens. January 2002;11:1-10.
55. Lin J, Valeri AM, Markowitz GS, et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation. 2002;73:783-788.
56. Calo LA, Davis PA, Giacon B, et al. Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002;400:625-631.
57. Asberg A, Midtvedt K, Vassbotn T, Hartmann A. Better microvascular function on long-term treatment wjth lisinopril than with nifedipine in renal transplant recipients. Nephrol Dial Transplant. 2001;16:1465-1470.
58. Ersoy A, Dilek K, Usta M, et al. Angiotensin-II receptor antagonist losartan reduces microalbuminuria in hypertensive renal transplant recipients. Clin Tramplant. 2002;16:202-205.
59. Schmidt A, Gruber U, Bohmig G, Koller E, Mayer G. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant. 2001;16:1034-1037.
60. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Post-transplant erythrocytosis. Kidney Int. 2003;63:1187-1194.
61. Glicklich D, Kapoian T, Mian H, Gilman J, Tellis V, Crizat H. Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis. Transplantation. July 1999;68:62-66.
62. Mazzali M, Filh GA. Use of aminophylline and enalapril in posttransplant polycythemia. Transplantation. 1998;65:1461-1464.
63. Yildiz A, Cine N, Akkaya V, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation. 2001;72:542-544.
64. The ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-1975.